The aim of this retrospective study was to investigate whether several variables like clinicopathological information at the time of diagnosis (PSA, clinical tumor-stage, International Society of Urological Pathology Grade Group and whether 68Ga-PSMA PET/CT was used for primary staging), treatment (RT/RP and histopathology of the prostatectomies), and pre-PET PSA could serve as possible predictors of the detection rate of 68Ga-PSMA PET/CT in patients with recurrent disease. The gene discussed is FOLH1; the disease is neoplasm.